TNRX-257 / Tentarix Biotherap - LARVOL DELTA

TNRX-257, a multifunctional LAG3 antagonist and conditional IL2Rϒ/ß partial agonist, is a novel immune stimulant with high dose tolerability in non-human primates (SITC 2023) - "TNRX-257 bioactivity was seen at both day 5 and day 7 post-dosing, as increases in the percentage of Ki67 positive NK cells, CD4 and CD8 T cells over the pre-dose level with the higher dose. Conclusions These data show that TNRX-257 has pharmacokinetics, bioactivity and a unique safety profile that support its clinical development for treating multiple cancer indications."

IO biomarker • Oncology • CD4 • CD8 • IL2 • IL2RA • LAG3

TNRX-257, a novel multifunctional biologic effectively blocks LAG3 and conditionally delivers IL2Rg/b agonism to LAG3+ cells for robust anti-tumor immunity (AACR 2023) - "TNRX-257 blocks the interaction of LAG3 with MHC-II and enhances TCR signaling with similar potency as Relatlimab. In contrast, the corresponding untargeted IL2Rγ/β Tentacle had no efficacy. Together, these data show that TNRX-257 has drug-like properties and elicits strong anti-tumor efficacy, supporting its clinical development."

IO biomarker • Colorectal Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • IL15 • LAG3